Loomis, Sayles & Company’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.5M | Buy |
170,982
+108,438
| +173% | +$20.1M | 0.04% | 168 |
|
|
2025
Q4 | $12.5M | Buy |
+62,544
| New | +$11.3M | 0.02% | 322 |
|
|
2023
Q2 | – | Sell |
-48,953
| Closed | -$9.88M | – | 990 |
|
|
2023
Q1 | $9.88M | Sell |
48,953
-8,991
| -16% | -$2.04M | 0.02% | 332 |
|
|
2022
Q4 | $12.6M | Sell |
57,944
-1,251
| -2% | -$273K | 0.03% | 282 |
|
|
2022
Q3 | $11.7M | Buy |
59,195
+709
| +1% | +$153K | 0.02% | 288 |
|
|
2022
Q2 | $12.5M | Buy |
58,486
+28,835
| +97% | +$7.05M | 0.02% | 330 |
|
|
2022
Q1 | $8.42M | Sell |
29,651
-34,911
| -54% | -$10.8M | 0.01% | 381 |
|
|
2021
Q4 | $24.3M | Sell |
64,562
-15,661
| -20% | -$6.08M | 0.03% | 281 |
|
|
2021
Q3 | $33.1M | Sell |
80,223
-37,702
| -32% | -$15.7M | 0.04% | 234 |
|
|
2021
Q2 | $43.6M | Buy |
117,925
+4,629
| +4% | +$1.55M | 0.05% | 186 |
|
|
2021
Q1 | $32.8M | Buy |
113,296
+85
| +0.1% | +$23.6K | 0.04% | 214 |
|
|
2020
Q4 | $28.3M | Buy |
113,211
+26,885
| +31% | +$6.4M | 0.04% | 218 |
|
|
2020
Q3 | $19.5M | Sell |
86,326
-31,903
| -27% | -$6.62M | 0.03% | 237 |
|
|
2020
Q2 | $20.6M | Buy |
118,229
+9,068
| +8% | +$1.45M | 0.03% | 216 |
|
|
2020
Q1 | $13.8M | Buy |
109,161
+20,155
| +23% | +$3.02M | 0.03% | 242 |
|
|
2019
Q4 | $13.6M | Buy |
89,006
+7,515
| +9% | +$1.04M | 0.02% | 290 |
|
|
2019
Q3 | $10.8M | Buy |
+81,491
| New | +$10.9M | 0.02% | 333 |
|
|
2019
Q2 | – | Sell |
-174
| Closed | -$25K | – | 605 |
|
|
2019
Q1 | $25K | Sell |
174
-6
| -3% | -$788 | ﹤0.01% | 601 |
|
|
2018
Q4 | $20K | Sell |
180
-24
| -12% | -$3K | ﹤0.01% | 696 |
|
|
2018
Q3 | $27K | Buy |
204
+126
| +162% | +$15.6K | ﹤0.01% | 695 |
|
|
2018
Q2 | $9K | Sell |
78
-184
| -70% | -$19.9K | ﹤0.01% | 800 |
|
|
2018
Q1 | $28K | Sell |
262
-7
| -3% | -$755 | ﹤0.01% | 720 |
|
|
2017
Q4 | $29K | Buy |
269
+43
| +19% | +$4.68K | ﹤0.01% | 704 |
|
|
2017
Q3 | $24K | Sell |
226
-46
| -17% | -$4.73K | ﹤0.01% | 736 |
|
|
2017
Q2 | $28K | Buy |
272
+17
| +7% | +$1.56K | ﹤0.01% | 704 |
|
|
2017
Q1 | $23K | Hold |
255
| – | – | ﹤0.01% | 756 |
|
|
2016
Q4 | $19K | Buy |
+255
| New | +$19.4K | ﹤0.01% | 793 |
|
|
2016
Q2 | – | Sell |
-54
| Closed | -$4K | – | 1028 |
|
|
2016
Q1 | $4K | Hold |
54
| – | – | ﹤0.01% | 950 |
|
|
2015
Q4 | $4K | Hold |
54
| – | – | ﹤0.01% | 945 |
|
|
2015
Q3 | $3K | Buy |
+54
| New | +$3.88K | ﹤0.01% | 971 |
|
Other funds holding CRL
VCM
VPM
Loomis, Sayles & Company's CRL Position: Q1 2026 in Review
Loomis, Sayles & Company increased its Charles River Laboratories (CRL) stake by 173% in Q1 2026, buying an estimated $20.1M and bringing the position to 170,982 shares worth $29.5M. The position accounts for 0.04% of the portfolio, ranked #168.
Loomis, Sayles & Company first reported a position in CRL in Q3 2015 and has held it in 30 quarters since. The position peaked at $43.6M in Q2 2021. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Loomis, Sayles & Company held 170,982 shares of Charles River Laboratories worth $29.5M as of Q1 2026.
- Loomis, Sayles & Company bought 108,438 Charles River Laboratories shares in Q1 2026, an estimated $20.1M.
- Charles River Laboratories made up 0.04% of Loomis, Sayles & Company's portfolio in Q1 2026, its #168 holding.
- Loomis, Sayles & Company first reported a position in Charles River Laboratories in Q3 2015 and has held it in 30 quarters since.
- Loomis, Sayles & Company's Charles River Laboratories position peaked at $43.6M in Q2 2021.
- 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.